METTL3 may serve as an oncogene in bladder cancer, contributes to cell proliferation and drives tumorigenesis, which is mediated by interacting with DGCR8 and subsequently accelerating the pri‐miR221/222 process in an m6A‐dependent manner concomitant with PTEN down‐regulation, and METTL3 correlates with poor prognosis and may be proposed as a potential therapeutic target for bladder cancer.108. This evidence concerns the gene METTL3 and urinary bladder cancer.